We will be in Strasbourg on Tuesday and Wednesday next Week for Biofit 2017 event. We will have a booth on Eurasante space.

We will present our new robotic platform, HAPIx, dedicated to HCS and our new assays, especially on genotoxicity analysis (mutiparametric assay with micronucleus, gH2AX and PHH3 analysis in a same experiment).

We will present also our collaborative R&D programs on iPS, 3D culture and innovative 3D cellular models for phenotypic screening!

We will be really happy to discuss with you on our booth. Contact us now if you want to book a meeting. See you next week in Strasbourg!

Last friday (10/11), we presented our neurotoxicity and genotoxicity assays at the French Agency for Food and Safety (ANSES). The ANSES had organized a meeting between different public screening platform facilities,  who used high content screening technologies.

We were kindly invited to present our platforms, and how HCS Pharma is involved in the development of innovative assays. Those events are a good way to start new collaborations, and we want to thanks Kevin Hogeveen, from Fougères laboratory who organized this meeting.

It was the first time HCS Pharma participate at 35th symposium of the French society of genetic toxicology (SFTG) as a sponsor. The implication of the SFTG in the study and assessment of environmental genotoxic agents motive us to be a sponsor of this 35th event.

This year, topic focused on the trans generational genotoxic and epigenetic effects of environmental compounds. Two high level plenary session, presented by Francelyne Marano and Giacomo Cavalli from CNRS, has introduced clearly the different implications of trans generational genotoxicity and epigenetic effects. The role of germinal cells was clearly established in exposition to genotoxic compounds and we were pleased to see clinicians and lab scientists exchanged about this topic.

We also presented our last assay on micronucleus and gamma H2AX detection to the SFTG community. Thanks to the positive feedback received after the presentation, we are confident in the quality and robusteness of our automated genotoxicity assays.

If you want more information about this symposium, you can check the twitter account of the SFTG on @SFTGene

Genotoxicity potential assessment of pharmaceuticals is mandatory for registration. In addition to the standard in vitro/ in vivo test battery, other assays can be of interest because of their high throughput in the drug discovery stage but also for mechanistic understanding.

Different other assays can be performed to detect DNA damage, such as γH2AX and the single cell gel electrophoresis (or comet assay).

keratinocyte2The γH2AX assay was suggested as a new in vitro assay for detecting genotoxic properties of chemicals. The phosphorylation of γH2AX has been demonstrated to be a sensitive marker for a wide range of DNA damage. In this study, primary human keratinocytes were evaluated to provide a more relevant testing system for genotoxicity assessment in the skin for topical dermatological/cosmetic substances. Primary human keratinocytes were compared to the well known HepG2 cell line for which data have already been published.

The comet assay is a sensitive, well established technique for quantifying DNA damage in eukaryotic cells and enabling the detection of a wide range of DNA damaging agents. The assay can be adapted in a 96 wells format allowing higher throughput.

The high content imaging (HCI) analysis applied to genotoxicity assays is a valuable tool allowing higher throughput and multi-parametric analysis in order to improve predictability of these assays.

View and download on Slideshare (low quality) : http://fr.slideshare.net/hcspharma/use-of-automated-high-content-analysis-or-imaging-applied-to-assessment-of-primary-dna-damage-with-h2ax-and-comet-assays-on-different-cell-types

Ask for high quality link  by putting your email below

Cell biology is part of the R&D activity in dermocosmetology. At HCS Pharma, we are developing new democosmetology assays on human primary keratinocytes using our automation plateform and high content analysis suite.

Assessment of compounds activity/safety can be performed on several parameters (wound healing, hydration, inflammation, toxicity, genotoxicity). Further parameters could be analyzed on demand using probes and immunocytochemistry.

Thought the use of high content analysis technologies, we can provide a wide range of results from phenotypes quantification cell by cell to live cells imaging movies.

View and download on Slideshare (low quality) : http://fr.slideshare.net/hcspharma/in-vitro-dermocosmetology-high-content-analysis-approach-using-human-primary-keratinocytes

Ask for high quality link  by putting your email below

If you are in Cosm’ing meeting, don’t hesitate to go and discuss with Julian BURSZTYKA, our COO. He presents our work in HCS Pharma by showing a poster on genotoxicity assay, developped in collaboration with Toxicology in vitro team of Galderma R&D and he will give a presentation at 9.15 am on the interest of using cell imaging for your R&D projects.

Bannière cosm'ing

HCSPharma-Galderma

During ELRIGfr event in Rennes, We had the opportunity to present our work on genotoxicity assay (comet assay on TK6 & gH2AX on keratinocytes and HepG2) in collaboration with the team of in vitro of Galderma R&D. It is really exciting to work with them since they are really experts in their domain and they want to work on innovative solutions in HCS. We really want to thank them for our interesting discussion and our collaborative projects!

HCSPharma-Galderma

PosterGenotoxHCSPharma-Galderma

Quantifying DNA damage is mandatory to assess potential adverse effects of candidate drugs or molecules or extracts developed in the dermo-cosmetic industry, but also to assess the efficacy of therapeutic approaches with the aim of producing tumor cell genotoxicity in cancer treatment.

The comet assay is a sensitive, well established technique for quantifying DNA damage in eukaryotic cells. Compatible with the detection of a wide range of DNA damaging agents, its principle consists in the migration of fragmented DNA in an electrophoresis gel (damaged DNA forming the tail of the comet), while intact DNA moves at a slower rate (head of the comet). The percentage of fragmented DNA in the comet tail is a direct measure of DNA damage.

View and download on Slideshare (low quality) :
http://fr.slideshare.net/hcspharma/development-of-an-automated-comet-assay-for-genotoxicity-assessment-on-tk6-cell-line

Ask for high quality link by putting your email below

I was present at the last congress ELRIGfr in Brussels. It was a strong exchange place with interesting presentations around robotics. It is always really interesting to see examples of innovative automation which give really robust results. For example, Frank Gudermann from university of Bielefield in Germany showed that automation of culture cell with cell count by holographic picture gives more robust results as manual count by trypan blue. Or automation of PK sampling with nanoliter by using echo technology allows increasing throughput of bioanalytical analysis for PK studies in Hoffmann La Roche. Also, another presentation of IGR has shown a complete robotic platform with 4 imagers (Micro from MDS) and 1 FACS totally automated from cell seeding to staining and reading.

It was a great pleasure also for us to present 4 different posters on our few last month works in cell imaging. This work was done in collaboration with Perkin Elmer on the Operetta machine. This machine allows us to take images in a 3D culture as shown in these posters: neuroprotection model for parkinson disease and oncology and performed also really nice images showed in these other posters: hepatotoxicity assay and genotoxicity assays.

Nathalie and Julian were present during ELRIGfr event last week. They presented their company, their work and their collaborations. They have also presented two posters : the first one on a co-culture model of Parkinson and first results in 3 dimensions ; the other one on genotoxicity and steatosis assays on HepG2 cells. These next two to three months will be dedicated to validate these assays. New assays  will also be undertaken, like transporters assays, cholestasis or phospholipidosis, on HepG2 cells as well as on primary hepatotocytes. Genotoxicity assays are under validation on different cell lines as HepG2, SH-SY5Y, HeLa, HT29 cells. If you want more details, don’t hesitate to contact us.

%d bloggers like this: